Natural Investments LLC Has $835,000 Position in Haleon PLC Sponsored ADR $HLN

Natural Investments LLC decreased its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 48.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 89,579 shares of the company’s stock after selling 83,397 shares during the quarter. Natural Investments LLC’s holdings in Haleon were worth $835,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. IHT Wealth Management LLC increased its stake in shares of Haleon by 6.9% in the 4th quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock valued at $164,000 after buying an additional 1,049 shares during the period. National Bank of Canada FI lifted its stake in shares of Haleon by 6.7% during the third quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock valued at $156,000 after acquiring an additional 1,099 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Haleon by 4.7% during the fourth quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock valued at $250,000 after acquiring an additional 1,100 shares during the period. Cary Street Partners Financial LLC boosted its holdings in Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after acquiring an additional 1,113 shares during the last quarter. Finally, Advisory Services Network LLC boosted its holdings in Haleon by 7.1% in the third quarter. Advisory Services Network LLC now owns 17,431 shares of the company’s stock valued at $156,000 after acquiring an additional 1,155 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on HLN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research note on Monday, August 24th. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Finally, Zacks Research raised shares of Haleon from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Haleon currently has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of HLN stock opened at $10.09 on Wednesday. The stock has a market cap of $44.38 billion, a PE ratio of 25.87, a price-to-earnings-growth ratio of 2.01 and a beta of 0.12. The stock has a 50-day moving average of $9.85 and a 200-day moving average of $9.78. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. Haleon PLC Sponsored ADR has a one year low of $8.65 and a one year high of $11.28.

Haleon Cuts Dividend

The company also recently announced a dividend, which will be paid on Thursday, September 17th. Shareholders of record on Friday, August 14th will be issued a $0.0642 dividend. The ex-dividend date is Friday, August 14th. This represents a yield of 132.0%. Haleon’s dividend payout ratio (DPR) is 30.77%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.